Vancomycin therapeutic guidelines: A summary of consensus recommendations from the infectious diseases society of america, the american society of health-system pharmacists, and the society of infectious diseases pharmacists

Michael J. Rybak, Ben M. Lomaestro, John C. Rotschafer, Robert C. Moellering, Willam A. Craig, Marianne Billeter, Joseph R. Dalovisio, Donald P. Levine

Research output: Contribution to journalShort surveypeer-review

571 Scopus citations

Abstract

Practice guidelines for therapeutic monitoring of vancomycin treatment for Staphylococcus aureus infection in adult patients were reviewed by an expert panel of the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. A literature review of existing evidence regarding vancomycin dosing and monitoring of serum concentrations, in addition to patient outcomes combined with expert opinion regarding the drug's pharmacokinetic, pharmacodynamic, and safety record, resulted in new recommendations for targeting and adjustment of vancomycin therapy.

Original languageEnglish (US)
Pages (from-to)325-327
Number of pages3
JournalClinical Infectious Diseases
Volume49
Issue number3
DOIs
StatePublished - Aug 1 2009

Bibliographical note

Funding Information:
Potential conflicts of interest. M.J.R. received research grants from Astellas, Cubist, Forest, and Pfizer; consulted for Astellas, Cubist, Forest, Ortho-McNeil, and Targanta; and has served on speakers’ bureaus for Cubist, Wyeth, Pfizer, and Targanta. J.C.R. has received research grants from Ortho-McNeil and Astra-Zeneca; has been a consultant for Ortho-McNeil, Schering, Cubist, Wyeth, Pfizer, Theravance, Optimer, and Bayer; and has served on speakers’ bureaus for Ortho-McNeil, Schering, Pfizer, Wyeth, and Cubist. R.C.M. was a former consultant for Eli Lilly. W.A.C. has received research funding from Johnson & Johnson and Astra-Zeneca and has been a consultant for Bristol-Myers Squibb and Forest Pharmaceuticals. M.B. has received research funding from Cubist and has served on speakers’ bureaus for Sanofi-Pasteur, Pfizer, and Ortho-McNeil. J.R.D. has received a consulting fee to testify on Capitol Hill regarding the clinical impact of the methicillin-resistant S. aureus outbreak in the United States; no product-specific data were discussed. B.M.L. and D.P.L.: no conflicts.

Fingerprint

Dive into the research topics of 'Vancomycin therapeutic guidelines: A summary of consensus recommendations from the infectious diseases society of america, the american society of health-system pharmacists, and the society of infectious diseases pharmacists'. Together they form a unique fingerprint.

Cite this